Cbay stock forecast.
At the close of trading, the stock’s price was $2.30, to imply a decrease of -3.77% or -$0.09 in intraday trading. The ATUS share’s 52-week high remains $5.57, putting it -142.17% down since that peak but still an impressive 12.61% since price per share fell to its 52-week low of $2.01.
The current CymaBay Therapeutics [ CBAY] share price is $17.90. The Score for CBAY is 74, which is 48% above its historic median score of 50, and infers lower risk than normal. CBAY is currently trading in the 70-80% percentile range relative to its historical Stock Score levels.Get the latest CymaBay Therapeutics Inc (CBAY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Their UBER share price targets range from $41.00 to $72.00. On average, they anticipate the company's stock price to reach $56.72 in the next twelve months. This suggests that the stock has a possible downside of 1.7%. View analysts price targets for UBER or view top-rated stocks among Wall Street analysts.Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Digital Turbine Inc have a median target of 5.50, with a high estimate of 12.00 and a low estimate of 5.00. The median ...
Investors often compare top stocks against the Russell 3000 Index, a broad measure of the U.S. stock market comprising 3,000 large publicly traded companies or 96% of the investable U.S. equity ...CBAY Earnings Date and Information. CymaBay Therapeutics last announced its quarterly earnings results on November 7th, 2023. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing …
The above table shows the analyst CBAY forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$18.03Find the latest CymaBay Therapeutics, Inc. (CBAY) stock quote, history, news and other vital information to help you with your stock trading and investing.
Insiders who bought CymaBay Therapeutics, Inc. (NASDAQ:CBAY) stock lover the last 12 months are probably not as affected by last week’s 11% loss.After accounting for the recent loss, the US$161k ...Xenon Pharmaceuticals Inc. 28.97. +0.24. +0.84%. Get CymaBay Therapeutics Inc (CBAY:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Wall Street Stock Market & Finance report, prediction for the future: You'll find the CBAK Energy Technology share forecasts, stock quote and buy / sell signals below. According to present data CBAK Energy Technology's CBAT shares and potentially its market environment have been in bearish cycle last 12 months (if exists). VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83.
16 brokerages have issued 1-year price targets for Exelixis' stock. Their EXEL share price targets range from $18.00 to $32.00. On average, they expect the company's stock price to reach $25.44 in the next twelve months. This suggests a possible upside of 19.6% from the stock's current price. View analysts price targets for EXEL or view top ...
Stock Price Forecast The 9 analysts offering 12-month price forecasts for Blink Charging Co have a median target of 5.00, with a high estimate of 25.00 and a low estimate of 3.00.
EXEL Stock 12 Months Forecast. Based on 13 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $25.75 with a high forecast of $32.00 and a low forecast of $18.00. The average price target represents a 25.06% change from the last price of $20.59.When planning outdoor activities or making travel arrangements, having access to accurate weather forecasts is crucial. One commonly used tool is the 7 day weather forecast, which provides an outlook for the upcoming week.CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce ...AC Immune S.A. analyst ratings, historical stock prices, earnings estimates & actuals. ACIU updated stock price target summary.Future criteria checks 2/6. CymaBay Therapeutics is forecast to grow earnings and revenue by 47.6% and 61.6% per annum respectively. EPS is expected to grow by 45.7% per annum. Return on equity is forecast to be -57.1% in 3 years.Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...
Ra Medical Systems, Inc (NYSE:RMED) released its quarterly earnings results on Monday, November, 15th. The company reported ($57.50) earnings per share for the quarter, missing the consensus estimate of ($39.50) by $18.00. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.70 million.Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Spruce Biosciences Inc have a median target of 8.50, with a high estimate of 10.00 and a low estimate of 7.00. The median ...The 12 analysts offering 1 year price forecasts for CBAY have a max estimate of — and a min estimate of —. Analyst rating Based on 13 analysts giving stock ratings to CBAY in the past 3 months. Shares of CymaBay Therapeutics ( CBAY -1.16%) were jumping 14.2% higher as of 10:54 a.m. ET on Friday. This move came on the heels of an 8.5% gain on Thursday. The continued momentum is a result ...Nov 6, 2023 · CBAY stock has been performing well according to 12 analysts offering 12-month price forecasts. The median target price is $22.50, with a high estimate of $33.00 and a low estimate of $19.00. This indicates a potential increase of 37.95% from the last recorded price of $16.31. The consensus among 13 polled investment analysts is to buy stock in ... Nov 1, 2021 · For CymaBay Therapeutics stock forecast for 2023, 1 predictions are offered for each month of 2023 with average CymaBay Therapeutics stock forecast of $19.97, a high forecast of $19.97, and a low forecast of $19.97. The average CymaBay Therapeutics stock forecast 2023 represents a 4.58% increase from the last price of $19.1000003814697.
Investors often compare top stocks against the Russell 3000 Index, a broad measure of the U.S. stock market comprising 3,000 large publicly traded companies or 96% of the investable U.S. equity ...CBAY one year fore… Wednesday, November 23, 2022 Edit. emporia hotels in marriott. marriott hotels in emporia va. Quality Inn Emporia November 23, 2022 Edit. Jill Scott wallpaper. ... cbay stock forecast cnn. Based on 5 Wall Street analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. CBAY one year …
CymaBay Therapeutics Inc. (CBAY) Reports Q3 Loss, Misses Revenue Estimates. by Zacks Equity Research Published on November 10,2021. CymaBay Therapeutics Inc. (CBAY) delivered earnings and revenue ...Find the latest CymaBay Therapeutics Inc. CBAY analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating.Sep 19, 2023 · CymaBay Therapeutics, Inc. (CBAY) share price prediction for 2023, 2024, 2025, 2026 and 2027. CBAY one year forecast. Cymabay Therapeutics stock monthly and weekly ... View the latest CymaBay Therapeutics Inc. (CBAY) stock price, news, historical charts, analyst ratings and financial information from WSJ.há 6 dias ... ... CBAY's share price rises to $24.00, which is the median consensus price. At that level, CBAY's share price would be -31.87% below current price.CBAY Stock Shows Promising Performance: Analysts Predict 38.63% Increase CBAY stock had a promising performance on November 6, 2023, based on the information provided by CNN Money. The 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc have a median target of 22.50, with a high estimate of 33.00 and a low estimate of 19.00.Stock Price Forecast. The 14 analysts offering 12-month price forecasts for International Business Machines Corp have a median target of 145.00, with a high estimate of 179.00 and a low estimate ...
VKTX Signals & Forecast. The Viking Therapeutics stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some …
Their CBAY share price targets range from $12.00 to $34.00. On average, they expect the company's stock price to reach $22.27 in the next twelve months. This suggests a possible upside of 13.0% from the stock's current price. View analysts price …
Of course, the risk is real, too; not every penny stock is going to show th Risk and reward are the yin and yang of stock trading, the two opposite but essential ingredients in every market success.CymaBay Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. CBAY updated stock price target summary.Nov 30, 2023 · According to 11 stock analysts, the average 12-month stock price forecast for CBAY stock stock is $20.18, which predicts an increase of 23.35%. The lowest target is $12 and the highest is $33. On average, analysts rate CBAY stock stock as a strong buy. Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Nov 6, 2023 · CBAY stock has been performing well according to 12 analysts offering 12-month price forecasts. The median target price is $22.50, with a high estimate of $33.00 and a low estimate of $19.00. This indicates a potential increase of 37.95% from the last recorded price of $16.31. The consensus among 13 polled investment analysts is to buy stock in ... The CymaBay Therapeutics stock forecast for tomorrow is $ 19.01, which would represent a -0.48% loss compared to the current price. In the next week, the price of CBAY is expected to decrease by -5.95% and hit $ 17.96. As far as the long-term CymaBay Therapeutics stock forecast is concerned ... See CymaBay Therapeutics, Inc. (CBAY) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead ...Reported on 11/6/23. Get the latest CymaBay Therapeutics Inc (CBAY) real-time quote, historical performance, charts, and other financial information to help you make more …All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange ...Nov 13. 4.17%. $94.57. Check if AHPI Stock has a Buy or Sell Evaluation. AHPI Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Allied Healthcare Products News.
Stock Price Forecast. The 7 analysts offering 12-month price forecasts for Verastem Inc have a median target of 32.00, with a high estimate of 36.00 and a low estimate of 17.50. The median ...Based on 6 Wall Street analysts offering 12 month price targets for Aldeyra Therapeutics in the last 3 months. The average price target is $10.00 with a high forecast of $11.00 and a low forecast of $8.00. The average price target represents a 352.49% change from the last price of $2.21. Highest Price Target $11.00. Average Price Target $10.00.Predictions of CBAY stock price for tomorrow. 14-day Premium Trial Subscription Try For Free Get FreeInstagram:https://instagram. femff stock price todaymoomoo investmentjanus henderson balanced fundroundpoint home loan Based on short-term price targets offered by 11 analysts, the average price target for CymaBay Therapeutics Inc. comes to $24.45. The forecasts range from a low of $20.00 to a high of $34.00. block buster stockchat trading CBAY is pre-revenue, given its pre-clinical status. It recorded $30mm in cash on the balance sheet last report , with an additional $122mm in marketable securities. Subsequently, it had $150mm in ...Aug 2, 2022 · Against this backdrop, Wall Street believes CBAY's long-term growth narrative is strong and that its $3.26 share price reflects the ideal entry point. ... (See ABSI stock forecast on TipRanks) housing reits EXEL Stock 12 Months Forecast. Based on 13 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $25.75 with a high forecast of $32.00 and a low forecast of $18.00. The average price target represents a 25.06% change from the last price of $20.59.Weather forecasts play an essential role in our daily lives, helping us plan our activities and stay prepared for any weather conditions that may come our way. One of the most common types of forecasts is the 7-day weather forecast, which p...Find real-time NOK - Nokia Oyj stock quotes, company profile, news and forecasts from CNN Business.